Alectinib Approved for ALK-Positive Adjuvant NSCLC

Lung Cancer News

Alectinib Approved for ALK-Positive Adjuvant NSCLC
Lung CarcinomaCancer Of The LungNon-Small Cell Lung Cancer
  • 📰 Medscape
  • ⏱ Reading Time:
  • 24 sec. here
  • 24 min. at publisher
  • 📊 Quality Score:
  • News: 90%
  • Publisher: 55%

The approval makes alectinib the first ALK inhibitor approved for early-stage NSCLC.

in the adjuvant setting following tumor resection in patients with anaplastic lymphoma kinase –positive non–small cell lung cancer , as detected by an FDA-approved test.

The kinase inhibitor was previously approved as first- and second-line treatment for ALK-positive metastatic NSCLC. Patients had resectable stage IB to IIIA tumors with ALK rearrangements identified by a locally performed FDA-approved ALK test or by a centrally performed Ventana ALK CDx assay. The most common adverse reactions with alectinib, occurring in 20% or more patients, were hepatotoxicity, constipation, myalgia, COVID-19, fatigue, rash, and cough.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Medscape /  🏆 386. in US

Lung Carcinoma Cancer Of The Lung Non-Small Cell Lung Cancer Nsclc Anaplastic Lymphoma Kinase ALK ALK Tyrosine Kinase Receptor CD246 Cluster Of Differentiation 246 Anaplastic Lymphoma Kinase Inhibitor ALK Inhibitor Otolaryngology ENT Specialty Head And Neck Surgery ENT Speciality Tumor Chemotherapy Toxicology Toxicity Poisoning Toxins Small Cell Lung Cancer

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.
Read more »

It Takes a Village: Treating Patients for NSCLC Brain MetsIt Takes a Village: Treating Patients for NSCLC Brain MetsTreatment decisions for patients with NSCLC metastasized to the brain should involve a multidisciplinary team, considering factors such as immunotherapy efficacy and optimal treatment sequences.
Read more »

Amivantamab Offers Post-Progression Benefit in EGFRm NSCLCAmivantamab Offers Post-Progression Benefit in EGFRm NSCLCEven if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.
Read more »

Tax breaks to hire local journalists approved in New York, a national firstTax breaks to hire local journalists approved in New York, a national firstThe incentive is intended to help the struggling local news industry.
Read more »

The first Apple-approved emulators for the iPhone have arrivedThe first Apple-approved emulators for the iPhone have arrivedThere is now a Game Boy emulator on the iOS App Store called iGBA that appears to be a direct copy of AltStore developer Riley Testut’s GBA4iOS, but with lots of trackers.
Read more »

Salvage crews mobilize as first $60 million approved for Baltimore bridge disasterSalvage crews mobilize as first $60 million approved for Baltimore bridge disasterSalvage crews began their trip Thursday to the Francis Scott Key Bridge's wreck site as both incoming commercial ships and first responders have found a helping hand from the shaken but resolute nearby community.
Read more »



Render Time: 2025-02-19 18:04:37